CD63 and breast carcinoma: Additionally, breast cancer MDA-MB-231 cells showed increased EVs (approximately 1.5-fold) after paclitaxel treatment, in which survivin-carrying EVs were upregulated, although exosomal CD63-carrying EVs were downregulated (88).